Navigation Links
Vasogen Provides Corporate Update
Date:7/3/2008

MISSISSAUGA, ON, July 3 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that it has implemented additional restructuring plans to further reduce its cash burn rate. As previously announced, the Company has been exploring strategic alternatives that may include potential acquisitions and mergers. In conjunction with this process, the Company has also completed an extensive review of its VP series of drugs, and has determined that it is in the best interest of its shareholders to halt expenses associated with the VP program while it completes its strategic review process.

"While we maintain our belief in the science underlying both Celacade and our VP series of drugs, the Board believes that the decision announced today is necessary in order to further conserve cash resources while completing the Company's ongoing strategic review process," commented Chris Waddick, President and CEO of Vasogen.

Certain statements in this press release constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to resume operations, to advance the development of the Celacade(TM) System or our VP series of drugs including VP015 and VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of our strategic review, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2007, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Vasogen Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference
2. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price
3. Vasogen Announces Implementation of Strategic Restructuring Plan
4. Vasogen Announces First Quarter 2008 Results
5. Vasogen to Webcast its Annual Meeting
6. Vasogen Provides Update on ACCLAIM II Program
7. Vasogen to Present at the BIO CEO & Investor Conference and Participate on the Non-Cancer Immunotherapy Panel
8. Vasogens Research Published in European Journal of Neuroscience
9. The Lancet Publishes Vasogens ACCLAIM Results
10. Vasogen Announces 2007 Year-End Results
11. Vasogen to Conduct Year-end 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... ... of Common Lisp (CL) development tools, and market leader for Semantic Graph ... performance enhancements now available within the most effective system for developing and deploying ...
(Date:4/25/2017)... ... April 25, 2017 , ... Leaders of Quorum Review ... be featured in multiple sessions at this week’s Association of Clinical Research Professionals ... best practices in clinical research. , "We are excited to present subject matter expertise ...
(Date:4/21/2017)... ... April 21, 2017 , ... The University ... first round funding to three startups through the UConn Innovation Fund. The $1.5 ... business startups affiliated with UConn. , The UConn Innovation Fund provides investments of ...
(Date:4/20/2017)... ... April 20, 2017 , ... As ... webinar will explore challenging patient cases when screening for direct oral anticoagulant. When ... be a need for bridging parental anticoagulation especially for those at high risk ...
Breaking Biology Technology:
(Date:3/30/2017)... -- On April 6-7, 2017, Sequencing.com will host the world,s ... at Microsoft,s headquarters in Redmond, Washington ... health and wellness apps that provide a unique, personalized ... is the first hackathon for personal genomics and the ... the genomics, tech and health industries are sending teams ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... -- The report "Gesture Recognition and Touchless Sensing Market by Technology ... Forecast to 2022", published by MarketsandMarkets, the market is expected to be worth ... and 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):